

Supplementary Table 3. The monthly proportion of glomerulonephritis at Severance Hospital after the initiation of nationwide vaccine program (after April 2021) based on the Bayesian structural time-series models

Pathologic finding	Observed value	Predicted value (95% CI)	Absolute effect (95% CI)	Posterior probability of causal impact (%) ^a	Posterior tail-area probability p-value
Total	1.19	1.18 (1.00–1.30)	0.01 (–0.14 to 0.16)	53.99	0.460
AIN	2.43	1.47 (0.41–2.50)	0.96 (–0.11 to 2.00)	96.17	0.038
ATI	1.97	1.60 (0.34–2.90)	0.37 (–0.92 to 1.60)	71.16	0.288
IgAN	38.57	37.95 (32.00–44.00)	0.61 (–5.20 to 6.30)	57.90	0.421
MN	6.48	6.90 (4.40–9.50)	–0.43 (–3.00 to 2.10)	63.22	0.368
Nonspecific histology	6.59	4.08 (2.00–6.20)	2.51 (0.37 to 4.60)	98.90	0.011
Other nephropathies	12.23	15.70 (12.00–20.00)	–3.47 (–7.40 to 0.42)	95.59	0.044
IC-GN	9.72	10.77 (6.40–15.00)	–1.05 (–5.40 to 3.30)	68.44	0.316
Pauci-immune crescentic GN	2.62	6.33 (3.60–9.10)	–3.71 (–6.40 to –1.00)	99.68	0.003
Podocytopathy	18.82	13.70 (9.50–18.00)	5.12 (0.80 to 9.30)	98.94	0.011
Thrombotic microangiopathy	0.57	1.60 (0.30–2.90)	–1.03 (–2.40 to 0.27)	93.91	0.061

AIN, acute interstitial nephritis; ATI, acute tubular injury; CI, confidence interval; GN, glomerulonephritis; IC-GN, immune complex-mediated GN; IgAN, immunoglobulin A nephropathy; MN, membranous nephropathy.

^aProbability threshold, 95%.